Aarti Drugs Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Net profit of Aarti Drugs declined 11.57% to Rs 35.01 crore in the quarter ended September 2024 as against Rs 39.59 crore during the previous quarter ended September 2023. Sales declined 6.74% to Rs 598.33 crore in the quarter ended September 2024 as against Rs 641.54 crore during the previous quarter ended September 2023.

Powered by Capital Market - Live News

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 24 October 2024.

Powered by Capital Market - Live News

The company said that there are no financial or material impacts as of now. With the GMP compliance, Pinnacle is positioned to export its formulations to the UK market.

The firm stated that there have been no violations or alleged contraventions regarding its operations.

Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals.

The company’s consolidated net profit declined 30.5% to Rs 33.24 crore on 16% slide in net sales to Rs 555.34 crore in Q1 FY25 over Q1 FY24.

Powered by Capital Market - Live News

The API inspection was conducted from 12 September to 20 September 2024. At the conclusion of the inspection, the USFDA issued a Form FDA 483, which included seven inspectional observations. Notably, none of the observations were related to data integrity.

The company stated that it will work closely with USFDA to resolve all points raised during the inspection.

Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals.

The company’s consolidated net profit declined 30.5% to Rs 33.24 crore on 16% slide in net sales to Rs 555.34 crore in Q1 FY25 over Q1 FY24.

The scrip advanced 1.16% to ends at Rs 524.80 on Friday, 20 September 2024.

Powered by Capital Market - Live News